EMA makes new rec­om­men­da­tions for Im­bru­vi­ca, med­i­cines with ter­li­pressin over res­pi­ra­to­ry and car­dio­vas­cu­lar risks

The EMA is hand­ing out a new rec­om­men­da­tion sur­round­ing J&J and Ab­b­Vie’s can­cer drug Im­bru­vi­ca and some med­i­cines con­tain­ing ter­li­pressin.

On Fri­day, the EMA’s safe­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER